Key clinical point: Liraglutide plus lifestyle therapy in adolescents with obesity led to greater reductions in BMI, compared with lifestyle therapy alone.
Major finding: Participants in the liraglutide group also saw a greater reduction in BMI compared with those in the placebo group (estimated difference, 4.64 percentage points).
Study details: A 56-week, randomized, controlled, double-blind trial with 251 adolescents (aged 12-17 years) with obesity.
Disclosures: Several of the authors reported that they are employees of Novo Nordisk, which funded the research.
Kelly AS et al. N Engl J Med. 2020 Mar 31. doi: 10.1056/NEJMoa1916038.